Maternal exposure to di-(2-ethylhexyl) phthalate disrupts placental growth and development in pregnant mice

•The influence of DEHP on the development of placenta was investigated.•DEHP disrupts the growth and development of placenta.•DEHP disrupts the formation of labyrinth vascularization.•DEHP inhibits the proliferation of ectoplacental cone and placenta.•DEHP induces the apoptosis of placenta via activ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hazardous materials 2015-10, Vol.297, p.25-33
Hauptverfasser: Zong, Teng, Lai, Lidan, Hu, Jia, Guo, Meijun, Li, Mo, Zhang, Lu, Zhong, Chengxue, Yang, Bei, Wu, Lei, Zhang, Dalei, Tang, Min, Kuang, Haibin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•The influence of DEHP on the development of placenta was investigated.•DEHP disrupts the growth and development of placenta.•DEHP disrupts the formation of labyrinth vascularization.•DEHP inhibits the proliferation of ectoplacental cone and placenta.•DEHP induces the apoptosis of placenta via activated MAPK signaling pathway. Di-(2-ethylhexyl) phthalate (DEHP) is used as a plasticizer and widely dispersed in the environment. DEHP exposure reduces embryo implantations, increases embryonic loss, and decreases fetal body weights. However, no detailed information is available about the effect of DEHP on the placentation during pregnancy. Thus, our aim was to explore the effect of DEHP on the growth and development of placenta in vivo. Mice were administered DEHP by gavages at 125, 250, 500mg/kg/day from gestational days (GD) 1 until sacrifice. Results showed that DEHP treatment significantly reduced the weight of placenta at GD 13. Histopathologically, in DEHP-treated group, the ectoplacental cones significantly became smaller at GD9, and total area of placenta and area of spongiotrophoblast were significantly reduced at GD 13. Expression levels of Ascl2, Esx1 and Fosl1 mRNA dramatically decreased in DEHP-treated placenta at GD 13. DEHP administration disrupted labyrinth vascularization of placentas, and inhibited proliferation and induced apoptosis of placenta by the activation of caspase-3 and -8, up-regulation of Bax and down-regulation of Bcl-2 mRNA and protein at GD 13. In conclusion, these results suggest that adverse pregnancy outcomes including low birth-weight and pregnancy loss exposed to DEHP are possibly mediated, at least in part, via the suppression of placental growth and development.
ISSN:0304-3894
1873-3336
DOI:10.1016/j.jhazmat.2015.04.065